Loading
Latest filing published 03 Jan 2022 for Matinas BioPharma Holdings, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Matthew Wikler in Matinas BioPharma Holdings, Inc., where the filings describe the role as board member. In total, 20 filings cover trades dated from 30 March 2018 to 31 December 2021.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
On 3 January 2022 came the latest disclosure, a share grant in Matinas BioPharma Holdings, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations